Saumen Chattopadhyay says Gilead Sciences will remain the leader in Hepatitis C treatment, and will maintain a strong leadership position. He notes that driving growth for the company remains to be its solid HIV product portfolio, but that forward P/E multiples have compressed over the last year. For this reason, Vertex Pharmaceuticals is his top pick in the biotech space, as it now is trading below the historical average. Tom White then looks at example trades in both Vertex Pharmaceuticals and Gilead Sciences.
Morning Trade Live
18 Mar 2022
SHARE
Market On Close
10 Jan 2023
Market On Close
31 Jan 2023
Trading 360
03 Mar 2023
Morning Trade Live
09 Mar 2023
The Watch List
27 Feb 2023